Regeneron Pharmaceuticals | REGN - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 645M 69M 2026-03
Agenus USD 14.67M 1.35M 2026-03
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Alnylam Pharmaceuticals USD 82.05M 12.76M 2026-06
Amgen USD 95.64B 94.98B 2026-06
Astellas Pharma JPY 3.91B 320M 2025-03
AstraZeneca USD 340M 144M 2026-06
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 63.29M 48.34M 2026-06
Bristol-Myers Squibb USD 407M 4M 2026-06
Eli Lilly USD 114.7M 134.3M 2025-09
Gilead Sciences USD 247M 7M 2026-06
GlaxoSmithKline GBP 121M 46M 2026-06
Incyte USD 582K 13K 2026-06
Ionis Pharmaceuticals USD 18M 1000K 2026-06
J&J USD 43M 25M 2026-03
Kyowa Hakko Kirin JPY 2.27B 1.84B 2026-03
Merck USD 525M 46M 2026-06
Moderna USD 10.96B 527M 2026-06
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 462M 119M 2026-06
Novartis USD 281M 8M 2025-09
Pfizer USD 667M 4M 2026-06
Puma Biotechnology USD 3.37M 11K 2024-06
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Roche Holding CHF 304M 7.5M 2025-06
Sanofi EUR -25M 99.78M 2025-12
Sarepta Therapeutics USD 21.51M 205K 2026-06
Teva Pharmaceutical Industries USD 195M 21M 2026-06
Ultragenyx Pharmaceutical USD 22M 1000K 2026-06
United Therapeutics USD 2.9M 200K 2026-06
Vertex Pharmaceuticals USD 3.3M 0 2025-12